Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years

Research output: Contribution to journalArticle

Abstract

Aim: The industry of unproven stem cell clinics has rapidly mushroomed throughout the USA, posing risks to patients and the research field. In this study, the aim was to better define how this industry changes. Methods: I analyzed a large cohort of US stem cell clinic firms and their distinct clinic locations as defined in 2015-2016 for their status now in 2019. Results: About a quarter of the firms no longer marketed stem cells. Some lacked active websites, while others dropped stem cell services. Even so, the total number of clinics in this group increased because some firms greatly expanded their clinic numbers. Conclusion: Overall, the unproven clinic industry is a moving target requiring ongoing study and regulatory oversight.

Original languageEnglish (US)
Pages (from-to)735-740
Number of pages6
JournalRegenerative Medicine
Volume14
Issue number8
DOIs
StatePublished - Jan 1 2019

Fingerprint

Stem cells
Stem Cells
Industry
Websites
Research

Keywords

  • bioethics
  • FDA
  • regenerative medicine
  • stem cell clinics

ASJC Scopus subject areas

  • Biomedical Engineering
  • Embryology

Cite this

Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years. / Knoepfler, Paul S.

In: Regenerative Medicine, Vol. 14, No. 8, 01.01.2019, p. 735-740.

Research output: Contribution to journalArticle

@article{4463f7c79c4742b4b6506ba23d83bca5,
title = "Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years",
abstract = "Aim: The industry of unproven stem cell clinics has rapidly mushroomed throughout the USA, posing risks to patients and the research field. In this study, the aim was to better define how this industry changes. Methods: I analyzed a large cohort of US stem cell clinic firms and their distinct clinic locations as defined in 2015-2016 for their status now in 2019. Results: About a quarter of the firms no longer marketed stem cells. Some lacked active websites, while others dropped stem cell services. Even so, the total number of clinics in this group increased because some firms greatly expanded their clinic numbers. Conclusion: Overall, the unproven clinic industry is a moving target requiring ongoing study and regulatory oversight.",
keywords = "bioethics, FDA, regenerative medicine, stem cell clinics",
author = "Knoepfler, {Paul S}",
year = "2019",
month = "1",
day = "1",
doi = "10.2217/rme-2019-0064",
language = "English (US)",
volume = "14",
pages = "735--740",
journal = "Regenerative Medicine",
issn = "1746-0751",
publisher = "Future Medicine Ltd.",
number = "8",

}

TY - JOUR

T1 - Rapid change of a cohort of 570 unproven stem cell clinics in the USA over 3 years

AU - Knoepfler, Paul S

PY - 2019/1/1

Y1 - 2019/1/1

N2 - Aim: The industry of unproven stem cell clinics has rapidly mushroomed throughout the USA, posing risks to patients and the research field. In this study, the aim was to better define how this industry changes. Methods: I analyzed a large cohort of US stem cell clinic firms and their distinct clinic locations as defined in 2015-2016 for their status now in 2019. Results: About a quarter of the firms no longer marketed stem cells. Some lacked active websites, while others dropped stem cell services. Even so, the total number of clinics in this group increased because some firms greatly expanded their clinic numbers. Conclusion: Overall, the unproven clinic industry is a moving target requiring ongoing study and regulatory oversight.

AB - Aim: The industry of unproven stem cell clinics has rapidly mushroomed throughout the USA, posing risks to patients and the research field. In this study, the aim was to better define how this industry changes. Methods: I analyzed a large cohort of US stem cell clinic firms and their distinct clinic locations as defined in 2015-2016 for their status now in 2019. Results: About a quarter of the firms no longer marketed stem cells. Some lacked active websites, while others dropped stem cell services. Even so, the total number of clinics in this group increased because some firms greatly expanded their clinic numbers. Conclusion: Overall, the unproven clinic industry is a moving target requiring ongoing study and regulatory oversight.

KW - bioethics

KW - FDA

KW - regenerative medicine

KW - stem cell clinics

UR - http://www.scopus.com/inward/record.url?scp=85072083063&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85072083063&partnerID=8YFLogxK

U2 - 10.2217/rme-2019-0064

DO - 10.2217/rme-2019-0064

M3 - Article

VL - 14

SP - 735

EP - 740

JO - Regenerative Medicine

JF - Regenerative Medicine

SN - 1746-0751

IS - 8

ER -